NCT04432688View on ClinicalTrials.gov

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

CompletedOBSERVATIONAL

Enrollment

3,192

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

March 18, 2023

Study Completion Date

June 18, 2023

Conditions

Schizophrenia

Interventions

DRUG

Lurasidone HCl

This is a non-interventional, observational study

Trial Locations (7)

100088

Beijing Anding Hospital, Beijing

150056

The first specialized hospital of Harbin, Harbin

200030

Shanghai Mental Health Center, Shanghai

250014

Shandong Mental Health Center, Jinan

300074

Tianjin Anding Hospital, Tianjin

410000

Brain Hospital of Hunan Province, Changsha

030001

First Affiliated Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors

lead

Sumitomo Pharma (Suzhou) Co., Ltd.

INDUSTRY

NCT04432688 - The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients | Biotech Hunter | Biotech Hunter